Janux Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 110 |
| Balance Sheets | 112 |
| Statements of Operations and Comprehensive Loss | 113 |
| Statements of Stockholders’ Equity | 114 |
| Statements of Cash Flows | 115 |
| Notes to Financial Statements | 116 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.